DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for isolated cleft palate — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIsolated cleft palate maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for isolated cleft palate is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
platelet derived growth factor receptor alpha (PDGFRA) — PDGFRA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet dimethylaminodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5GRN · 1.77 Å · ligand N-[2-(dimethylamino)ethyl]-N-[[4-[[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]carbamoyl]phenyl]methyl]pyridine-3-carboxamide (748). Experimental structure, not a prediction.
What the evidence adds up to
No drug is tested or repurposed for isolated cleft palate in these abstracts. The 2015 review states that no universal agreement exists on surgical technique and that well-controlled prospective studies are needed to validate claims of superior results. The 2022 commentary focuses on opioid use in surgical care for cleft lip and palate, summarising strategies to minimise perioperative opioid prescribing through holistic, multidisciplinary approaches. The 2020 review notes that more than 100 genes have been associated with cleft lip and palate but that the pathological mechanism of these genes has not been delineated; it summarises several signal pathways involved in lip and palate development but does not report any drug intervention.
No survival or response rates are given because no drug trial is described. The abstracts contain no efficacy data, no repurposed drug, and no concrete numbers for any treatment outcome. The only numerical claim is that more than 100 genes have been linked to the condition, with no mechanism confirmed.
What is missing is any clinical trial of a drug for isolated cleft palate, any patient stratification by genetic or molecular subtype, and any funding for prospective, controlled studies that move beyond surgical technique or opioid management.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Cleft Lip Palate and Craniofacial Anomalies · 2015 · 5 citations · open access
Repair of cleft palate: Evolution and current trends
AbstractThe management of a patient with cleft palate is complex. Various prevalent surgical techniques are presented, but no universal agreement exists on the appropriate treatment strategy. There is a consensus of opinion that normal speech should be the most important consideration in the therapeutic plan. Growth disturbance should be minimized, but not at the expense of speech impairment because facial distortion can be satisfactorily managed by surgery, whereas speech impairment can often be irreversible. There is a need for well-controlled, prospective studies to establish the validity of the widely different claims of superior results from various techniques. Cleft patients should be managed in a center with a multidisciplinary team. Cleft palate remains a significant and interesting challenge for current and future plastic surgeons.
Perspectives of the ASHA Special Interest Groups · 2022 · 0 citations
The Use of Opioids in the Surgical Care of Patients With Orofacial Clefts: A Commentary and Guide to Management
AbstractPurpose: This commentary outlines the surgical pathway for patients with cleft lip and/or palate (CLP), identifies risks associated with opioid prescribing in this patient population, and summarizes strategies to safely minimize the need for perioperative opioid prescribing. Conclusions: Patients with orofacial clefts, CLP, undergo multiple reconstructive surgeries. The long-term effects of perioperative opioid prescriptions should concern all members of the cleft and craniofacial team. The amount of surgery each patient with a CLP may face varies by patient and can begin in infancy and continue to adulthood. In this commentary, the surgical pathway for CLP is reviewed, and the opioid crisis is addressed in regard to this vulnerable patient group. Solutions for cleft and craniofacial team members from evidence-based literature are summarized to minimize the use of opioids prescribed in this patient population. Approaches to reduce opioid use after CLP surgery are holistic and multidisciplinary.
[Key signaling pathways associated with risks forcleft lip and palate].
AbstractThe molecular mechanism of cleft lip and palate has been a hot topic for research in recent years. With the development of genetic technology, more than 100 genes have been associated with cleft lip and palate, though the pathological mechanism of such genes has not been delineated.The information carried by each of these genes may affect the phenotype through signal pathway, and abnormal function of these signal pathways has been found in the formation of cleft lip and palate. A series of signal factors have known to involve in the regulation of gene expression, and may interact with each other to form complex signal regulatory networks which are involved in the guidance of cell activity and tissue formation. This article has summarized several signal pathways related to lip and palate, and the molecular mechanism underlying the development of lip and palate.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
